Bristol-Myers Squibb Company

05/27/2022 | Press release | Distributed by Public on 05/27/2022 16:13

U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell[...]